Related Experiment Videos
Endotracheal instillation of prostacyclin in preterm infants with persistent pulmonary hypertension
A P De Jaegere1, J N van den Anker
1Dept of Pediatrics, Erasmus University and University Hospital Rotterdam/Sophia Children's Hospital, The Netherlands.
Insights
Endotracheal prostacyclin (epoprostenol) significantly improved oxygenation in preterm infants with persistent pulmonary hypertension by reducing pulmonary vascular resistance. This novel delivery method showed sustained benefits without systemic side effects.
Area of Science:
- Neonatal Medicine
- Pediatric Pulmonology
- Pharmacology
Background:
- Persistent pulmonary hypertension of the newborn (PPHN) is a critical condition in preterm infants.
- Current treatments for PPHN have limitations and potential side effects.
Purpose of the Study:
- To investigate the efficacy of endotracheal prostacyclin (epoprostenol) in improving oxygenation in preterm infants with PPHN.
- To assess the impact of endotracheal prostacyclin on systemic circulation and evaluate for side effects.
Main Methods:
- Four preterm infants with PPHN were studied.
- Prostacyclin was administered via endotracheal bolus (50 ng x kg(-1)), with repeated or continuous administration in some cases.
- Oxygenation was assessed using the oxygenation index and PaO2/FiO2 ratio; mean arterial blood pressure monitored systemic circulation.
Main Results:
- Endotracheal prostacyclin significantly decreased the oxygenation index and increased the PaO2/FiO2 ratio, indicating improved oxygenation.
- These improvements were attributed to reduced pulmonary vascular resistance and reversal of extrapulmonary shunting.
- No significant changes in mean arterial blood pressure were observed, and effects reversed upon drug withdrawal.
- Sustained response without tachyphylaxis or overt side effects was noted with repeated or continuous administration.
Conclusions:
- Endotracheal instillation of prostacyclin is an effective method for improving oxygenation in preterm infants with PPHN.
- This approach offers localized pulmonary effects without systemic vascular repercussions.
- Sustained efficacy and safety profile suggest potential as a therapeutic option for PPHN.
Abstract:
Does endotracheal instilled prostacyclin (epoprostenol) improve oxygenation in preterm infants with persistent pulmonary hypertension? Four preterm infants were studied. Prostacyclin (50 ng x kg(-1)) was injected as an endotracheal bolus. In two patients the prostacyclin bolus was repeated and in one patient prostacyclin was administered continuously. Oxygenation was evaluated through the oxygenation index and the ratio of arterial oxygen tension to the fraction of inspired oxygen. The mean arterial blood pressure was used to evaluate systemic circulation. The oxygenation index (+/-SD) decreased significantly from 39 (+/-13.3) to 7 (+/-2.5) and the ratio of arterial oxygen tension to the fraction of inspired oxygen (+/-SD) increased significantly from 47 (+/-13) to 218 (+/-67), most likely related to a reduction of the pulmonary vascular resistance with a reversal of the extrapulmonary shunting at the ductus arteriosus and atrial level. The blood pressure did not change. All effects were reversed on drug withdrawal. Repeated or continuous endotracheal administration of prostacyclin in three children demonstrated a sustained response without tachyphylaxis, and without overt side-effects. Endotracheal instillation of prostacyclin resulted in an improved oxygenation without systemic vascular repercussions in four preterm infants with persistent pulmonary hypertension. Repeated or continuous administration showed a sustained response and no overt side-effects were noticed.